Full-Time

Ex-Vivo Clinical Specialist 2

United Therapeutics Corporation

United Therapeutics Corporation

Biotech company develops PAH therapies

No salary listed

Jacksonville, FL, USA

In Person

Must live within a one-hour drive of the Jacksonville office. Relocation assistance is available.

Bachelor's, Associate's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Microsoft Office
Word/Pages/Docs
Quality Assurance (QA)
Data Analysis
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Requirements
  • An Associate Degree in a related field, or commensurate experience and/or combination of education and experience, is required.
  • Have 4+ years of experience as a Procurement Transplant Coordinator with critical care experience managing donor patients and an Associate's Degree, or 2+ years of experience as a Procurement Transplant Coordinator with critical care experience managing donor patients and a Bachelor's Degree.
  • Have 2+ years of experience in two of the following three areas: sterile technique, direct participation in surgical procedures, or critical care including ventilator management and blood gas interpretation.
  • Upon hire, be able to train onsite in Jacksonville, Florida and Silver Spring, Maryland.
  • Successfully pass any qualification requirements upon completion of initial training.
  • Demonstrate specialized knowledge of lung physiology and mechanics.
  • Be skilled in data collection and analysis.
  • Be able to operate Apple and PC devices and use Microsoft Office Suite, including Word, Excel, Outlook, and PowerPoint, as well as Adobe Acrobat.
  • Be able to follow procedures and demonstrate competency in sterile technique and basic surgical skills, including suturing and tying.
Responsibilities
  • Coordinate clinical team arrival at the Lung Bioengineering EVLP facility for surgical suite setup.
  • Prepare and set up EVLP systems and equipment according to established protocols.
  • Create and control an aseptic zone.
  • Evaluate physical lung condition and lead surgical cannulation and reconstruction of vessels and trachea.
  • Operate and maintain the EVLP system and associated equipment.
  • Manage all aspects of the EVLP procedure, including lung assessment, venous gas sampling, bronchoscopy, X-ray collection, recruitment, and deflation.
  • Collect and conduct laboratory tests and analysis on preserved lungs to evaluate suitability for transplant.
  • Maintain communication with Lung Bioengineering Medical Consultants and the accepting transplant surgeon.
  • Address and resolve medical, safety, and eligibility questions from accepting transplant centers.
  • Monitor adherence to protocols and determine EVLP case completion with the Lung Bioengineering Medical Consultant and accepting surgeon.
  • Follow OPTN lung packaging procedures and prepare the surgical area for the next EVLP procedure.
  • Assist the transplant center with post-EVLP logistics.
  • Adhere to safety protocols and procedures, including proper handling and disposal of hazardous materials and surgical waste.
  • Maintain regulatory compliance frameworks associated with clinical procedures, including FDA, UNOS, OPTN, CLIA, and CMS requirements at the U.S. federal and state levels, as well as Health Canada requirements.
  • Participate in clinical review meetings and other administrative and scientific activities.
  • Participate in quality control and quality assurance activities, including deviation documentation and SOP review.
  • Collaborate and perform experiments with pre-clinical and translational medicine colleagues to assess potential new lung therapeutic development as needed.
  • Attend staff meetings and provide input into operational, clinical, and regulatory development plans as needed.
  • Adhere to the on-call schedule and support regular daytime office hours.
  • Work within all applicable Lung Bioengineering policies and procedures.
  • Work with the contracted call center to triage incoming EVLP referrals.
  • Evaluate donor lung suitability from Organ Procurement Organization or transplant center EVLP referrals.
  • Review donor medical charts to confirm device inclusion and exclusion criteria.
  • Initiate referral documentation in Lung Bioengineering’s data collection platform.
  • Assist in identifying EVLP transplant centers at the request of the Organ Procurement Organization.
  • Assist the Organ Procurement Organization or transplant center with pre-EVLP logistics to ensure organs arrive within the timeframe required to execute the EVLP procedure.
  • Perform all other required duties.
Desired Qualifications
  • Bachelor’s Degree in a related field, or commensurate experience and/or combination of education and experience.
  • 2+ years of experience in advanced practice organ procurement/transplant.
  • CPTC - Certified Procurement Transplant Coordinator.
United Therapeutics Corporation

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ralinepag met ADVANCE OUTCOMES primary endpoint and filed for FDA approval in 2026.
  • Thymmune’s $140 million acquisition expands regenerative medicine beyond pulmonary hypertension.
  • Q2 2026 cash generation funded buybacks, while LungFX services begin in 2027.

What critics are saying

  • Liquidia’s Yutrepia launched in 2025 and directly attacks Tyvaso DPI sales.
  • Watson can launch generic nebulized Tyvaso in January 2026, pressuring pricing.
  • PAH concentration creates existential risk if Tyvaso and Remodulin franchises erode together.

What makes United Therapeutics Corporation unique

  • United Therapeutics owns PAH franchises plus LungFX and xenotransplantation platforms.
  • LungFX PMA, approved June 29, 2026, strengthens its organ engineering moat.
  • Martine Rothblatt’s public-benefit mission attracts talent for long-horizon organ manufacturing work.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Holidays

Paid Vacation

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Professional Certification Support

Tuition Reimbursement

Stock Options

Company Equity

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Sabbatical Leave

Hybrid Work Options

Remote Work Options

Flexible Work Hours

ParentAL Leave

Company News

Yahoo Finance
Aug 7th, 2026
United Therapeutics reports $333M net income and $7.27 EPS as ralinepag files for FDA approval

United Therapeutics reported second-quarter 2026 results showing sales of $783.3 million, a slight year-on-year decline, whilst net income rose to $333 million and diluted earnings per share increased to $7.27. The company continued share repurchases under its $1.50 billion buyback programme, retiring 5.84% of shares. The biotech firm also published positive phase 3 ADVANCE OUTCOMES data for investigational pulmonary arterial hypertension therapy ralinepag and filed with the FDA. The stronger earnings per share partly reflects the shrinking share count from buybacks. Analysts remain divided on the company's future, with some projecting only 1.2% annual revenue growth and $1.4 billion earnings by 2029, citing concerns about its concentrated portfolio of pulmonary drugs and regulatory uncertainties.

Yahoo Finance
Jul 23rd, 2026
United Therapeutics appoints ex-National Academy of Medicine president Victor Dzau to board

United Therapeutics Corporation has appointed Victor Dzau to its board of directors, effective 22 July 2026. Dr Dzau recently completed a 12-year term as president of the National Academy of Medicine and previously served as chancellor for health affairs at Duke University and president of the Duke University Health System. Dr Dzau is recognised globally as a physician-scientist whose research laid the foundation for ACE inhibitors. He pioneered gene therapy for vascular disease and currently studies cardiac regeneration. Martine Rothblatt, chairperson and chief executive officer of United Therapeutics, said Dr Dzau is uniquely capable of guiding the company in its mission of developing transplantable organs and organ alternatives for patients with end-stage organ failure.

Yahoo Finance
Jul 11th, 2026
United Therapeutics wins FDA approval for LungFX device amid questions over valuation

United Therapeutics is under scrutiny after the US FDA approved its LungFX device for centralised ex vivo lung perfusion. The stock has shown strong momentum, with a year-to-date return of 10.13% and a one-year total shareholder return of 85.12%, though short-term prices have eased slightly. The company closed at $547.06, against a narrative fair value of $665.23, suggesting an 18% undervaluation. The valuation gap depends on whether LungFX, Tyvaso, and the broader pulmonary and organ platforms can drive future earnings. United Therapeutics' pipeline includes studies in progressive fibrosis, next-generation delivery platforms, and organ manufacturing technologies. However, the company faces risks from potential trial setbacks and drug pricing reforms that could impact profitability and cash flows.

Yahoo Finance
Jul 8th, 2026
United Therapeutics acquires Thymmune for $140M to advance organ transplant innovation

United Therapeutics Corporation acquired Thymmune Therapeutics for $140 million in cash, with potential additional earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031. Thymmune develops regenerative thymic cell therapies using human-induced pluripotent stem cells. The acquisition expands United Therapeutics' organ transplantation capabilities. The company focuses on treating life-threatening diseases, including pulmonary arterial hypertension, whilst addressing the global organ shortage through xenotransplantation, 3D bioprinting, and ex vivo lung perfusion technologies. Separately, the FDA granted premarket approval for LungFX, which Leerink Partners described as a regulatory advancement supporting the company's long-term organ manufacturing strategy. Leerink maintains an Outperform rating on United Therapeutics shares.

Citybiz
Jul 2nd, 2026
United Therapeutics expands regenerative medicine pipeline with $140M Thymmune acquisition.

United Therapeutics expands regenerative medicine pipeline with $140M Thymmune acquisition. July 2, 2026 United Therapeutics has acquired Thymmune Therapeutics, a privately held, preclinical biotechnology company developing regenerative thymic cell therapies, in a deal valued at $140 million upfront with the potential for an additional $160 million in milestone payments. Silver Spring, Maryland-based United Therapeutics (Nasdaq: UTHR) said the acquisition strengthens its regenerative medicine portfolio and supports its long-term strategy to expand the availability of transplantable organs while advancing cell-based therapies for immune-related diseases. Thymmune, based in Research Triangle Park, North Carolina, is developing scalable thymic cell therapies using induced pluripotent stem cells (iPSCs). Its proprietary platform is designed to generate thymic cells capable of restoring healthy T-cell function, with potential applications in organ transplant tolerance, immunodeficiencies and autoimmune diseases. The company's lead candidate, THY-100, is in preclinical development for congenital athymia, a rare and life-threatening disorder in which infants are born without a functional thymus. According to the company, preclinical animal studies have demonstrated the formation of a functional "neo-thymus" capable of supporting T-cell development. United Therapeutics said the technology also has broader potential in transplant tolerance, immune-mediated diseases and age-related declines in immune function. "Thymmune's platform complements United Therapeutics' broader mission to expand the supply of transplantable organs, building on our UThymoKidney clinical development program and our growing strength in immunomodulatory therapeutics," said Martine Rothblatt, Ph.D., chairperson and chief executive officer of United Therapeutics. "By restoring or modulating T-cell receptor diversity, Thymmune's technology could make fundamental contributions to human health care and potentially resolve the root causes of dozens of life-threatening diseases." Thymmune founder and CEO Stan Wang, M.D., Ph.D., said United Therapeutics' expertise in organ alternatives and regenerative medicine makes it well-positioned to advance the company's platform toward clinical development. Under the terms of the agreement, United Therapeutics paid $140 million in cash, subject to customary post-closing adjustments. Former Thymmune shareholders may also receive up to $160 million in additional earn-out payments tied to the achievement of specified clinical and regulatory milestones through the end of 2031. Founded in 1996 by Martine Rothblatt after her daughter was diagnosed with pulmonary arterial hypertension, United Therapeutics has grown from a rare disease drug developer into a diversified biotechnology company focused on pulmonary hypertension therapies, organ manufacturing, xenotransplantation and regenerative medicine. The company has invested heavily in developing manufactured organs and cell-based technologies aimed at addressing the shortage of transplantable organs. The acquisition comes as United Therapeutics continues to post strong financial results. For the first quarter of 2026, the company reported revenue of approximately $794 million, up from $677 million in the same period a year earlier, driven by continued growth across its pulmonary hypertension franchise. Net income totaled approximately $381 million for the quarter, and the company ended the period with more than $3 billion in cash and investments, providing substantial resources to fund acquisitions and advance its expanding research pipeline.